|本期目录/Table of Contents|

[1]曹振环,柳雅立,马丽娜,等.聚乙二醇干扰素治疗非活动性 HBsAg 携带者血清MIP-1β 水平变化趋势[J].传染病信息,2018,05:436-438.
 CAO Zhen-huan,LIU Ya-li,MA Li-na,et al.Changes of serum levels of MIP-1β in inactive hepatitis B surface antigen carriers treated with pegylated-interferon[J].Infectious Disease Information,2018,05:436-438.
点击复制

聚乙二醇干扰素治疗非活动性 HBsAg 携带者血清MIP-1β 水平变化趋势(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年05期
页码:
436-438
栏目:
专题论著
出版日期:
2018-10-30

文章信息/Info

Title:
Changes of serum levels of MIP-1β in inactive hepatitis B surface antigen carriers treated with pegylated-interferon
作者:
曹振环柳雅立马丽娜郑燕红王 群王俊丽吴芳芳陈新月
100069,首都医科大学附属北京佑安医院肝病综合 科(曹振环、柳雅立、马丽娜、郑燕红、王群、王俊丽、吴芳芳、陈新月)
Author(s):
CAO Zhen-huan LIU Ya-li MA Li-na ZHENG Yan-hong WANG Qun WANG Jun-li WU Fang-fang CHEN Xin-yue*
Department of Liver Diseases, Beijing You'an Hospital, Capital Medical University, 100069, China
关键词:
非活动性HBsAg 携带者聚乙二醇干扰素HBsAg 清除MIP-1β
Keywords:
 inactive HBsAg carriers pegylated-interferon HBsAg clearance MIP-1β  
分类号:
R512.62 
DOI:
10.3969/j.issn.1007-8134.2018.05.007
文献标识码:
A
摘要:
目的 探讨聚乙二醇干扰素(pegylated-interferon, Peg-IFN)治疗非活动性HBsAg 携带者(inactive hepatitis B surface antigen carrier, IHC)发生HBsAg 清除与血清MIP-1β 水平的相关性。方法 入组经Peg-IFN 治疗24 周的IHC 20 例, 其中13 例获得HBsAg 清除(R 组),7 例未获得HBsAg 清除(NR 组)。用Luminex 技术检测IHC 基线、治疗12 周和 治疗24 周血清巨噬细胞炎性蛋白1β(macrophage inflammatory protein-1β, MIP-1β)水平。同时检测11 例健康者(HC 组) 血清MIP-1β 水平。通过比较R 组与NR 组基线血清MIP-1β 水平及治疗后变化趋势,探讨血清MIP-1β 与HBsAg 清除的相 关性。结果 R 组、NR 组、HC 组基线血清MIP-1β 水平差异无统计学意义(F=0.320,P=0.729)。R 组经Peg-IFN 治疗 后MIP-1β 水平较基线明显下降(F=4.532,P=0.018)。而NR 组血清MIP-1β 呈水平波动,较基线无显著变化(F=0.071, P=0.932)。结论 经Peg-IFN 治疗后,IHC 的血清MIP-1β 水平明显降低,表明该治疗可能有利于HBsAg 的清除。 
Abstract:
 Objective To investigate the correlation of HBsAg clearance with serum MIP-1β level in inactive hepatitis B surface antigen carrier (IHC) treated with pegylated-interferon (Peg-IFN). Methods Twenty IHCs were enrolled in this study after 24 weeks of Peg-IFN treatment, including 13 patients achieving HBsAg clearance (R group) and 7 patients not achieving HBsAg clearance (NR group). Serum MIP-1β levels in IHCs were detected by Luminex technology at baseline after 12 weeks and 24 weeks of treatment. In addition, serum MIP-1β levels in 11 healthy controls (HC group) were detected. The correlation of serum MIP-1β with HBsAg clearance was investigated by comparing the baseline serum MIP-1β level and post-treatment trends of R and NR groups. Results There were no statistical significant differences of serum MIP-1β level between R, NR and HC groups (F=0.320, P=0.729). After Peg-IFN treatment, serum MIP-1β level decreased significantly in R group, comparing to baseline data (F=4.532, P=0.018). Serum MIP-1β level showed a horizontal fluctuation and no significantly change in NR group, comparing to baseline data (F=0.071, P=0.932). Conclusions After Peg-IFN treatment, serum MIP-1β level in IHC obviously decreases. This treatment may benefit HBsAg clearance.       

参考文献/References


[1] 中华医学会肝病学分会,中华医学会感染病学分会. 《慢性乙型肝炎防治指南》(2015 年更新版)[J]. 传染病信息,2015,28(6):321-340.
[2] Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactiveHBsAg carriers [J]. Hepatol Int, 2007, 1(2):311-315.
[3] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis Bvirus are still at risk for hepatocellular carcinoma and liver-relateddeath [J]. Gastroenterol, 2010, 138(5):1747-1754.
[4] Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viralinfection in inactive HBsAg carriers following anti-tumor necrosisfactor-alpha therapy[J]. J Rheumatol, 2009, 36(11):2416-2420.
[5] Hwang JP, Lok AS. Management of patients with hepatitis B whorequire immunosuppressive therapy[J]. Nat Rev GastroenterolHepatol, 2014, 11(4):209-219.
[6] Zhou K, Terrault N. Management of hepatitis B in specialpopulations[J]. Best Pract Res Clin Gastroenterol, 2017,31(3):311-320.
[7] Cao Z, Liu Y, Ma L, et al. A potent HBsAg response in subjectswith inactive HBsAg carrier treated with pegylated-interferonAlpha[J]. Hepatology, 2017, 66(4):1058-1066.
[8] Heinrichs D, Berres ML, Nellen A, et al. The chemokine CCL3promotes experimental liver fibrosis in mice[J]. PLoS One,2013, 17:8(6):e66106.
[9] Solé C, Solà E, Morales-Ruiz M, et al. Characterization ofinflammatory response in acute-on-chronic liver failure andrelationship with prognosis[J]. Sci Rep, 2016, 6:32341.
[10] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelinesfor treatment of chronic hepatitis B[J]. Hepatology, 2016,63(1):261-283.
[11] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practiceguidelines on the management of hepatitis B: a 2015 update [J].Hepatol Int, 2016, 10(1):1-98.
[12] Invernizzi F, Viganò M, Grossi G, et al. The prognosis andmanagement of inactive HBV carriers[J]. Liver Int, 2016, 36 (Suppl 1):S100-S104.
[13] Chu CM, Liaw YF. Incidence and risk factors of progression tocirrhosis in inactive carriers of hepatitis B virus[J]. Am JGastroenterol, 2009, 104(7):1693-1699.
[14] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis Bvirus are still at risk for hepatocellular carcinoma and liver-relateddeath [J]. Gastroenterol, 2010, 138(5):1747-1754.

备注/Memo

备注/Memo:
[ 基金项目] 国家“十三五”科技重大专项(2017ZX10202201); 首都临床特色应用研究与成果推广(Z161100000516018, Z171100001017062); 首都卫生发展科研专项( 首发2016-1- 2183,首发2018-2-2183);北京市自然科学基金(7182073); 北京市医院管理局“青苗”计划(QML20161701);北京市教育 委员会科技计划一般项目(KM201710025018);首都医科大学基 础与临床合作项目(17JL-07);首都医科大学重点实验室开放研 究课题(2-03-02-BJYAH2016001)
[ 作者单位] 100069,首都医科大学附属北京佑安医院肝病综合 科(曹振环、柳雅立、马丽娜、郑燕红、王群、王俊丽、吴芳芳、 陈新月)
[ 通信作者] 陈新月,E-mail: chenxydoc@163.com
更新日期/Last Update: 2018-10-30